Ironwood Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference

  Ironwood Pharmaceuticals to Present at Morgan Stanley Global Healthcare

Morgan Stanley Global Healthcare Conference 2013

Business Wire

CAMBRIDGE, Mass. -- September 3, 2013

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update
at the Morgan Stanley Global Healthcare Conference on Tuesday, September 10,
2013 at 4:05 p.m. Eastern Time at the Grand Hyatt New York.

A live webcast of Ironwood’s presentation will be accessible through the
Investors section of the company’s website at To
access the webcast, please log on to the Ironwood website approximately 15
minutes prior to the start time to ensure adequate time for any software
downloads that may be required. A replay of the webcast will be available on
Ironwood’s website for 14 days following the conference.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is committed to the art and science of
making medicines, from discovery through commercialization. We’re focused on
three goals: transforming knowledge into medicines that make a difference for
patients, creating value that will inspire the continued support of our fellow
shareholders, and building a team that passionately pursues excellence. Our
first product, linaclotide, is approved in the United States and Europe. Our
pipeline priorities include exploring further opportunities for linaclotide,
leveraging our deep expertise in functional gastrointestinal disorders, and
advancing programs in other areas such as allergic conditions, cardiovascular
disease, central nervous system disorders and other conditions defined by
patient symptoms.Ironwood was founded in 1998 and is headquartered in
Cambridge, Mass. Connect with us at or on Twitter at to learn more about Ironwood. Information that
may be important to investors will be routinely posted in both these


Ironwood Pharmaceuticals, Inc.
Media Relations
Lisa Buffington, 617-374-5103
Vice President, Corporate Communications
Investor Relations
Meredith Kaya, 617-374-5082
Director, Investor Relations
Press spacebar to pause and continue. Press esc to stop.